Ассоциация полиморфизма -1171 5A/6A гена матриксной металлопротеиназы 3-го типа (rs35068180) с дилатационной кардиомиопатией - Научно-практический журнал Cardioсоматика Том 11, №3 (2020)
Ассоциация полиморфизма -1171 5A/6A гена матриксной металлопротеиназы 3-го типа (rs35068180) с дилатационной кардиомиопатией
Кузнецова О.О., Никулина С.Ю., Чернова А.А., Максимов В.Н. Ассоциация полиморфизма -1171 5A/6A гена матриксной металлопротеиназы – 3-го типа (rs35068180) с дилатационной кардиомиопатией. CardioСоматика. 2020; 11 (3): 6–9. DOI: 10.26442/22217185.2020.3.200372
DOI: 10.26442/22217185.2020.3.200372
________________________________________________
DOI: 10.26442/22217185.2020.3.200372
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье представлено исследование полиморфных аллельных вариантов гена матриксной металлопротеиназы 3-го типа (MMP-3) -1171 5A/6A (rs35068180) у больных с дилатационной кардиомиопатией (ДКМ). Выявлен новый генетический предиктор развития ДКМ – аллель A и генотип 6А6А гена MMP-3 -1171 5A/6A (rs35068180).
Цель. Изучить ассоциацию полиморфизма -1171 5А/ гена MMP-3 с ДКМ различного генеза.
Материал и методы. Основная группа обследуемых – 221 пациент с ДКМ различного генеза, средний возраст – 55,30±9,69 года. Из них группа больных с дилатацией миокарда ишемического генеза (111 человек), среди которых
99 (89,2%) мужчин и 12 (10,8%) женщин. Из 221 больного у 110 пациентов не удалось верифицировать причину дилатации миокарда – идиопатическую ДКМ. В данной группе мужчин было 100 (91,5%), женщин – 10 (8,5%). Контрольная группа нашего исследования представлена 221 здоровым человеком без заболеваний сердечно-сосудистой системы. Средний возраст пациентов – 53,6±4,8 года. Всем пациентам основной группы проводились рутинные лабораторные, инструментальные методы обследования, а также коронарография, при подозрении на миокардит – магнитно-резонансная томография сердца. Всем пациентам выполнили генотипирование полиморфизма -1171 5A/6A (rs35068180) гена ММР-3 с помощью полимеразной цепной реакции.
Результаты. Среди пациентов основной группы с дилатационным ремоделированием миокарда различного генеза аллель 6A задокументирован в 65,8% случаев против 59,3% среди лиц контрольной группы, p=0,044. Гомозиготный генотип 6А6А гена ММР-3 у пациентов основной группы верифицирован у 42,1% пациентов против 32,6% случаев у относительно здоровых лиц (p=0,099).
Заключение. В группе пациентов с ДКМ доказано преобладание аллеля 6A и генотипа 6A6A гена ММР-3. Предполагаем, что гомозиготность по аллелю 6A приводит к снижению активности транскрипции, изменению уровня стромелизина в стенках артерий. Это способствует активации проколлагеназы 1-го типа, отложению внеклеточного матрикса и ремоделированию сердечной мышцы.
Ключевые слова: дилатационная кардиомиопатия, генетический полиморфизм, матриксная металлопротеиназа-3.
Aim. To study the association of polymorphism -1171 5A/ of the MMP-3 gene with dilated cardiomyopathy of various origins.
Material and methods. The main study group comprised 221 patients with dilated cardiomyopathy (DCM) of different origin. Their average age was 55.30±9.69 years. Among them there were 111 persons with DCM of ischemic origin, including 99 (89.2%) men and 12 (10.8%) women. The average age of the subjects with DCM was 51.73±9.74 years, the age of the male subgroup was 51.00±8.96 years, and the age of the female subgroup was 57.75±3.71 years. A total of 110 patients with idiopathic cardiomyopathy were included in the study. Among 221 patients, 110 persons did not demonstrated idiopathic dilated cardiomyopathy as the cause of myocardium dilation. This group comprised 100 (91.5%) male patients and 10 (8.5%) female patients. The control group of subjects (221 persons) was represented by healthy people without diseases of the cardiovascular system. The average age of control subjects was 53.6±4.8 years. We examined all patients in the main group using routine laboratory and instrumental methods, as well as coronary angiography. If myocarditis was suspected, we did an MRI of the heart. Genotyping of polymorphism
-1171 5A/6A (rs35068180) of the MMP-3 gene was performed using PCR.
Results. Among patients of the main group with dilated myocardial remodeling of various Genesis, the allele was documented in 65.8% of cases against 59.3% among the control group, p=0.044. The homozygous genotype of the MMP-3 gene in patients of the main group was verified in 42.1% of patients against 32.6% of cases in relatively healthy individuals (p=0.099).
Conclusion. We have proved the predominance of 6A allele and 6А6А genotype of the MMP-3 gene in the group of patients with DCM. It seems that it is homozygous 6A allele that causes a decrease in the activity of the transcription process and change in the level of stromelysin in arterial walls. This contributes to the activation of type 1 procollagenase, extracellular matrix deposition and cardiac muscle remodeling.
Key words: dilated cardiomyopathy, genetic polymorphism, matrix metalloproteinase-3.
Цель. Изучить ассоциацию полиморфизма -1171 5А/ гена MMP-3 с ДКМ различного генеза.
Материал и методы. Основная группа обследуемых – 221 пациент с ДКМ различного генеза, средний возраст – 55,30±9,69 года. Из них группа больных с дилатацией миокарда ишемического генеза (111 человек), среди которых
99 (89,2%) мужчин и 12 (10,8%) женщин. Из 221 больного у 110 пациентов не удалось верифицировать причину дилатации миокарда – идиопатическую ДКМ. В данной группе мужчин было 100 (91,5%), женщин – 10 (8,5%). Контрольная группа нашего исследования представлена 221 здоровым человеком без заболеваний сердечно-сосудистой системы. Средний возраст пациентов – 53,6±4,8 года. Всем пациентам основной группы проводились рутинные лабораторные, инструментальные методы обследования, а также коронарография, при подозрении на миокардит – магнитно-резонансная томография сердца. Всем пациентам выполнили генотипирование полиморфизма -1171 5A/6A (rs35068180) гена ММР-3 с помощью полимеразной цепной реакции.
Результаты. Среди пациентов основной группы с дилатационным ремоделированием миокарда различного генеза аллель 6A задокументирован в 65,8% случаев против 59,3% среди лиц контрольной группы, p=0,044. Гомозиготный генотип 6А6А гена ММР-3 у пациентов основной группы верифицирован у 42,1% пациентов против 32,6% случаев у относительно здоровых лиц (p=0,099).
Заключение. В группе пациентов с ДКМ доказано преобладание аллеля 6A и генотипа 6A6A гена ММР-3. Предполагаем, что гомозиготность по аллелю 6A приводит к снижению активности транскрипции, изменению уровня стромелизина в стенках артерий. Это способствует активации проколлагеназы 1-го типа, отложению внеклеточного матрикса и ремоделированию сердечной мышцы.
Ключевые слова: дилатационная кардиомиопатия, генетический полиморфизм, матриксная металлопротеиназа-3.
________________________________________________
Aim. To study the association of polymorphism -1171 5A/ of the MMP-3 gene with dilated cardiomyopathy of various origins.
Material and methods. The main study group comprised 221 patients with dilated cardiomyopathy (DCM) of different origin. Their average age was 55.30±9.69 years. Among them there were 111 persons with DCM of ischemic origin, including 99 (89.2%) men and 12 (10.8%) women. The average age of the subjects with DCM was 51.73±9.74 years, the age of the male subgroup was 51.00±8.96 years, and the age of the female subgroup was 57.75±3.71 years. A total of 110 patients with idiopathic cardiomyopathy were included in the study. Among 221 patients, 110 persons did not demonstrated idiopathic dilated cardiomyopathy as the cause of myocardium dilation. This group comprised 100 (91.5%) male patients and 10 (8.5%) female patients. The control group of subjects (221 persons) was represented by healthy people without diseases of the cardiovascular system. The average age of control subjects was 53.6±4.8 years. We examined all patients in the main group using routine laboratory and instrumental methods, as well as coronary angiography. If myocarditis was suspected, we did an MRI of the heart. Genotyping of polymorphism
-1171 5A/6A (rs35068180) of the MMP-3 gene was performed using PCR.
Results. Among patients of the main group with dilated myocardial remodeling of various Genesis, the allele was documented in 65.8% of cases against 59.3% among the control group, p=0.044. The homozygous genotype of the MMP-3 gene in patients of the main group was verified in 42.1% of patients against 32.6% of cases in relatively healthy individuals (p=0.099).
Conclusion. We have proved the predominance of 6A allele and 6А6А genotype of the MMP-3 gene in the group of patients with DCM. It seems that it is homozygous 6A allele that causes a decrease in the activity of the transcription process and change in the level of stromelysin in arterial walls. This contributes to the activation of type 1 procollagenase, extracellular matrix deposition and cardiac muscle remodeling.
Key words: dilated cardiomyopathy, genetic polymorphism, matrix metalloproteinase-3.
Список литературы
1. Elliott P, Andersson B, Arbustini E et al. Classification of the cardiomyopathies: a position statement from the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J 2008; 29 (2): 270–6. DOI: 10.1093/eurheartj/ehm342
2. Барт Б.Я., Беневская В.Ф. Дилатационная кардиомиопатия в практике терапевта и кардиолога (лекция). Терапевтический архив. 2004; 79 (1): 12–7.
[Bart B.Y., Benevskaya V.F. Dilated cardiomyopathy in therapeutic and cardiological practice (lecture). Therapeutic Archive. 2004; 79 (1): 12–7 (in Russian).]
3. Sugrue DD, Rodeheffer RJ, Codd MB et al. The clinical course of idiopathic dilated cardiomyopathy: A population-based study. Ann Intern Med 1992; 117 (2): 117–23. DOI: 10.7326/0003-4819-117-2-117
4. Startari U, Taylor MR, Sinagra G et al. Dilated cardiomyopathy: Etiology, clinical criteria for diagnosis and screening of the familial form. Ital Heart J Suppl 2002; 3 (4): 378–85.
5. Medley TL, Kingwell BA, Gatzka CD et al. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 2003; 92 (11): 1254–61. DOI: 10.1161/01.RES.0000076891.24317.CA
6. Капелько В.И. Ремоделирование миокарда: роль матриксных металлопротеиназ. Кардиология. 2001; 41 (6): 49–55.
[Kapelko V.I. Myocardial Remodeling: The Role of Matrix Metalloproteinases. Kardiologiia. 2001; 41 (6): 49–55 (in Russian).]
7. Li J, Schwimmbeck PL, Tschope C et al. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res 2002; 56 (2): 235–47. DOI: 10.1016/s0008-6363(02)00546-1
8. Benjamin IJ. Matrix metalloproteinases: from biology to therapeutic strategies in cardiovascular disease. J Investig Med 2001; 49 (5): 381–97. DOI: 10.2310/6650.2001.33783
9. Creemers EE, Cleutjens JP, Smits JF et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89 (3): 201–10. DOI: 10.1161/hh1501.094396
10. Hunt MJ, Aru GM, Hayden MR et al. Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol Lung Cell Mol Physiol 2002; 283 (2): L239. DOI: 10.1152/ajplung.00001.2002
11. Hojo Y, Ikeda U, Ueno S et al. Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn Circ J 2001; 65 (2): 71–5. DOI: 10.1253/jcj.65.71
12. Mittal B, Mishra A, Srivastava A et al. Matrix metalloproteinases in coronary artery disease. Adv Clin Chem 2014; 64: 1–72. DOI: 10.1016/b978-0-12-800263-6.00001-x
13. Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 2006; 69 (3): 636–45. DOI: 10.1016/j.cardiores.2005.07.015
14. Гайковая Л.Б., Кухарчик Г.А., Нестерова Н.Н. и др. Современные лабораторные маркеры в определении прогноза при остром коронарном синдроме и мониторинге терапии. Вестник аритмологии. 2009; 58: 52–9.
[Gaykovaya L.B., Kukharchik G.A., Nesterova N.N. et al. Modern laboratory markers in determining the prognosis for acute coronary syndrome and monitoring therapy. Journal of arrhythmology. 2009; 58: 52–9 (in Russian).]
15. Humphries SE, Martin S, Cooper J et al. Interaction between smoking and the stromelysin-1 (ММР-3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann Hum Genet 2002; 66 (5–6): 343–52.
16. Xu X, Wang L, Xu C et al. Variations in matrix metalloproteinase-1, -3, and -9 genes and the risk of acute coronary syndrome and coronary artery disease in the Chinese Han population. Coron Artery Dis 2013; 24 (4): 259–65. DOI: 10.1097/MCA.0b013e32835ea3af
17. Dunleavey L, Beyzade S, Ye S. Rapid genotype analysis of the stromelysin gene 5A/6A polymorphism. Atherosclerosis 2000; 151 (2): 587–9. DOI: 10.1016/S0021-9150(00)00443-3
18. Tang LJ, Chen XF, Zhu M et al. Matrix metalloproteinase-1, -3, and -9 gene polymorphisms and the risk of idiopathic dilated cardiomyopathy in a Chinese Han population. Clin Biochem 2007; 40 (18): 1427–30. DOI: 10.1016/j.clinbiochem.2007.09.013.
2. Bart B.Y., Benevskaya V.F. Dilated cardiomyopathy in therapeutic and cardiological practice (lecture). Therapeutic Archive. 2004; 79 (1): 12–7 (in Russian).
3. Sugrue DD, Rodeheffer RJ, Codd MB et al. The clinical course of idiopathic dilated cardiomyopathy: A population-based study. Ann Intern Med 1992; 117 (2): 117–23. DOI: 10.7326/0003-4819-117-2-117
4. Startari U, Taylor MR, Sinagra G et al. Dilated cardiomyopathy: Etiology, clinical criteria for diagnosis and screening of the familial form. Ital Heart J Suppl 2002; 3 (4): 378–85.
5. Medley TL, Kingwell BA, Gatzka CD et al. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 2003; 92 (11): 1254–61. DOI: 10.1161/01.RES.0000076891.24317.CA
6. Kapelko V.I. Myocardial Remodeling: The Role of Matrix Metalloproteinases. Kardiologiia. 2001; 41 (6): 49–55 (in Russian).
7. Li J, Schwimmbeck PL, Tschope C et al. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res 2002; 56 (2): 235–47. DOI: 10.1016/s0008-6363(02)00546-1
8. Benjamin IJ. Matrix metalloproteinases: from biology to therapeutic strategies in cardiovascular disease. J Investig Med 2001; 49 (5): 381–97. DOI: 10.2310/6650.2001.33783
9. Creemers EE, Cleutjens JP, Smits JF et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89 (3): 201–10. DOI: 10.1161/hh1501.094396
10. Hunt MJ, Aru GM, Hayden MR et al. Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol Lung Cell Mol Physiol 2002; 283 (2): L239. DOI: 10.1152/ajplung.00001.2002
11. Hojo Y, Ikeda U, Ueno S et al. Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn Circ J 2001; 65 (2): 71–5. DOI: 10.1253/jcj.65.71
12. Mittal B, Mishra A, Srivastava A et al. Matrix metalloproteinases in coronary artery disease. Adv Clin Chem 2014; 64: 1–72. DOI: 10.1016/b978-0-12-800263-6.00001-x
13. Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 2006; 69 (3): 636–45. DOI: 10.1016/j.cardiores.2005.07.015
14. Gaykovaya L.B., Kukharchik G.A., Nesterova N.N. et al. Modern laboratory markers in determining the prognosis for acute coronary syndrome and monitoring therapy. Journal of arrhythmology. 2009; 58: 52–9 (in Russian).
15. Humphries SE, Martin S, Cooper J et al. Interaction between smoking and the stromelysin-1 (ММР-3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann Hum Genet 2002; 66 (5–6): 343–52.
16. Xu X, Wang L, Xu C et al. Variations in matrix metalloproteinase-1, -3, and -9 genes and the risk of acute coronary syndrome and coronary artery disease in the Chinese Han population. Coron Artery Dis 2013; 24 (4): 259–65. DOI: 10.1097/MCA.0b013e32835ea3af
17. Dunleavey L, Beyzade S, Ye S. Rapid genotype analysis of the stromelysin gene 5A/6A polymorphism. Atherosclerosis 2000; 151 (2): 587–9. DOI: 10.1016/S0021-9150(00)00443-3
18. Tang LJ, Chen XF, Zhu M et al. Matrix metalloproteinase-1, -3, and -9 gene polymorphisms and the risk of idiopathic dilated cardiomyopathy in a Chinese Han population. Clin Biochem 2007; 40 (18): 1427–30. DOI: 10.1016/j.clinbiochem.2007.09.013.
2. Барт Б.Я., Беневская В.Ф. Дилатационная кардиомиопатия в практике терапевта и кардиолога (лекция). Терапевтический архив. 2004; 79 (1): 12–7.
[Bart B.Y., Benevskaya V.F. Dilated cardiomyopathy in therapeutic and cardiological practice (lecture). Therapeutic Archive. 2004; 79 (1): 12–7 (in Russian).]
3. Sugrue DD, Rodeheffer RJ, Codd MB et al. The clinical course of idiopathic dilated cardiomyopathy: A population-based study. Ann Intern Med 1992; 117 (2): 117–23. DOI: 10.7326/0003-4819-117-2-117
4. Startari U, Taylor MR, Sinagra G et al. Dilated cardiomyopathy: Etiology, clinical criteria for diagnosis and screening of the familial form. Ital Heart J Suppl 2002; 3 (4): 378–85.
5. Medley TL, Kingwell BA, Gatzka CD et al. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 2003; 92 (11): 1254–61. DOI: 10.1161/01.RES.0000076891.24317.CA
6. Капелько В.И. Ремоделирование миокарда: роль матриксных металлопротеиназ. Кардиология. 2001; 41 (6): 49–55.
[Kapelko V.I. Myocardial Remodeling: The Role of Matrix Metalloproteinases. Kardiologiia. 2001; 41 (6): 49–55 (in Russian).]
7. Li J, Schwimmbeck PL, Tschope C et al. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res 2002; 56 (2): 235–47. DOI: 10.1016/s0008-6363(02)00546-1
8. Benjamin IJ. Matrix metalloproteinases: from biology to therapeutic strategies in cardiovascular disease. J Investig Med 2001; 49 (5): 381–97. DOI: 10.2310/6650.2001.33783
9. Creemers EE, Cleutjens JP, Smits JF et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89 (3): 201–10. DOI: 10.1161/hh1501.094396
10. Hunt MJ, Aru GM, Hayden MR et al. Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol Lung Cell Mol Physiol 2002; 283 (2): L239. DOI: 10.1152/ajplung.00001.2002
11. Hojo Y, Ikeda U, Ueno S et al. Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn Circ J 2001; 65 (2): 71–5. DOI: 10.1253/jcj.65.71
12. Mittal B, Mishra A, Srivastava A et al. Matrix metalloproteinases in coronary artery disease. Adv Clin Chem 2014; 64: 1–72. DOI: 10.1016/b978-0-12-800263-6.00001-x
13. Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 2006; 69 (3): 636–45. DOI: 10.1016/j.cardiores.2005.07.015
14. Гайковая Л.Б., Кухарчик Г.А., Нестерова Н.Н. и др. Современные лабораторные маркеры в определении прогноза при остром коронарном синдроме и мониторинге терапии. Вестник аритмологии. 2009; 58: 52–9.
[Gaykovaya L.B., Kukharchik G.A., Nesterova N.N. et al. Modern laboratory markers in determining the prognosis for acute coronary syndrome and monitoring therapy. Journal of arrhythmology. 2009; 58: 52–9 (in Russian).]
15. Humphries SE, Martin S, Cooper J et al. Interaction between smoking and the stromelysin-1 (ММР-3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann Hum Genet 2002; 66 (5–6): 343–52.
16. Xu X, Wang L, Xu C et al. Variations in matrix metalloproteinase-1, -3, and -9 genes and the risk of acute coronary syndrome and coronary artery disease in the Chinese Han population. Coron Artery Dis 2013; 24 (4): 259–65. DOI: 10.1097/MCA.0b013e32835ea3af
17. Dunleavey L, Beyzade S, Ye S. Rapid genotype analysis of the stromelysin gene 5A/6A polymorphism. Atherosclerosis 2000; 151 (2): 587–9. DOI: 10.1016/S0021-9150(00)00443-3
18. Tang LJ, Chen XF, Zhu M et al. Matrix metalloproteinase-1, -3, and -9 gene polymorphisms and the risk of idiopathic dilated cardiomyopathy in a Chinese Han population. Clin Biochem 2007; 40 (18): 1427–30. DOI: 10.1016/j.clinbiochem.2007.09.013.
________________________________________________
2. Bart B.Y., Benevskaya V.F. Dilated cardiomyopathy in therapeutic and cardiological practice (lecture). Therapeutic Archive. 2004; 79 (1): 12–7 (in Russian).
3. Sugrue DD, Rodeheffer RJ, Codd MB et al. The clinical course of idiopathic dilated cardiomyopathy: A population-based study. Ann Intern Med 1992; 117 (2): 117–23. DOI: 10.7326/0003-4819-117-2-117
4. Startari U, Taylor MR, Sinagra G et al. Dilated cardiomyopathy: Etiology, clinical criteria for diagnosis and screening of the familial form. Ital Heart J Suppl 2002; 3 (4): 378–85.
5. Medley TL, Kingwell BA, Gatzka CD et al. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 2003; 92 (11): 1254–61. DOI: 10.1161/01.RES.0000076891.24317.CA
6. Kapelko V.I. Myocardial Remodeling: The Role of Matrix Metalloproteinases. Kardiologiia. 2001; 41 (6): 49–55 (in Russian).
7. Li J, Schwimmbeck PL, Tschope C et al. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res 2002; 56 (2): 235–47. DOI: 10.1016/s0008-6363(02)00546-1
8. Benjamin IJ. Matrix metalloproteinases: from biology to therapeutic strategies in cardiovascular disease. J Investig Med 2001; 49 (5): 381–97. DOI: 10.2310/6650.2001.33783
9. Creemers EE, Cleutjens JP, Smits JF et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89 (3): 201–10. DOI: 10.1161/hh1501.094396
10. Hunt MJ, Aru GM, Hayden MR et al. Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol Lung Cell Mol Physiol 2002; 283 (2): L239. DOI: 10.1152/ajplung.00001.2002
11. Hojo Y, Ikeda U, Ueno S et al. Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn Circ J 2001; 65 (2): 71–5. DOI: 10.1253/jcj.65.71
12. Mittal B, Mishra A, Srivastava A et al. Matrix metalloproteinases in coronary artery disease. Adv Clin Chem 2014; 64: 1–72. DOI: 10.1016/b978-0-12-800263-6.00001-x
13. Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 2006; 69 (3): 636–45. DOI: 10.1016/j.cardiores.2005.07.015
14. Gaykovaya L.B., Kukharchik G.A., Nesterova N.N. et al. Modern laboratory markers in determining the prognosis for acute coronary syndrome and monitoring therapy. Journal of arrhythmology. 2009; 58: 52–9 (in Russian).
15. Humphries SE, Martin S, Cooper J et al. Interaction between smoking and the stromelysin-1 (ММР-3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann Hum Genet 2002; 66 (5–6): 343–52.
16. Xu X, Wang L, Xu C et al. Variations in matrix metalloproteinase-1, -3, and -9 genes and the risk of acute coronary syndrome and coronary artery disease in the Chinese Han population. Coron Artery Dis 2013; 24 (4): 259–65. DOI: 10.1097/MCA.0b013e32835ea3af
17. Dunleavey L, Beyzade S, Ye S. Rapid genotype analysis of the stromelysin gene 5A/6A polymorphism. Atherosclerosis 2000; 151 (2): 587–9. DOI: 10.1016/S0021-9150(00)00443-3
18. Tang LJ, Chen XF, Zhu M et al. Matrix metalloproteinase-1, -3, and -9 gene polymorphisms and the risk of idiopathic dilated cardiomyopathy in a Chinese Han population. Clin Biochem 2007; 40 (18): 1427–30. DOI: 10.1016/j.clinbiochem.2007.09.013.
Авторы
О.О. Кузнецова1, С.Ю. Никулина*1, А.А. Чернова1, В.Н. Максимов1,2
1 ФГБОУ ВО «Красноярский государственный медицинский университет
им. проф. В.Ф. Войно-Ясенецкого» Минздрава России, Красноярск, Россия;
2 Научно-исследовательский институт терапии и профилактической медицины – филиал ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики СО РАН», Новосибирск, Россия
*nicoulina@mail.ru
1 Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia;
2 Institute of Internal and Preventive Medicine – a branch of the Federal Research Center Institute of Cytology and Genetics, Novosibirsk, Russia
*nicoulina@mail.ru
1 ФГБОУ ВО «Красноярский государственный медицинский университет
им. проф. В.Ф. Войно-Ясенецкого» Минздрава России, Красноярск, Россия;
2 Научно-исследовательский институт терапии и профилактической медицины – филиал ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики СО РАН», Новосибирск, Россия
*nicoulina@mail.ru
________________________________________________
1 Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia;
2 Institute of Internal and Preventive Medicine – a branch of the Federal Research Center Institute of Cytology and Genetics, Novosibirsk, Russia
*nicoulina@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.